Evidence map›Paper›PMID 40948833›Full record

ReviewTranslational lung cancer research2025

Deep learning enhances precision diagnosis and treatment of non-small cell lung cancer: future prospects.

Xinran Zhang, Jia Liu, Wen Zhou, Junfei Lu, Liqin Wu, Yan Li, Yiyuan Wang, Zhichao Wang, Jun Cai

Abstract readReview
In one paragraph

Review in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xinran Zhang *Department of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou, China.ORCID https://orcid.org/0009-0007-3669-2247
Jia Liu *Department of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou, China.
Wen ZhouDepartment of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou, China.
Junfei LuDepartment of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou, China.
Liqin WuDepartment of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou, China.
Yan LiDepartment of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou, China.
Yiyuan WangDepartment of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou, China.
Zhichao WangDepartment of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou, China.
Jun CaiDepartment of Oncology, The First Affiliated Hospital of Yangtze University, Jingzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC), a major form of pulmonary malignancy and a leading global cause of cancer-related mortality, highlights the urgent need for advanced precision treatment approaches. This article comprehensively reviews the significant progress and future directions of deep learning techniques in revolutionizing the precise diagnosis and therapeutic management of NSCLC. It demonstrates how deep learning methods have the potential to surpass traditional tumor treatment paradigms, significantly enhancing diagnostic accuracy, personalizing treatment selection, and predicting patient outcomes with greater precision. The article traces the evolution of deep learning models in this field, from basic analyses relying on single data modalities, such as imaging or genomics alone, to more sophisticated architectures capable of multimodal data fusion. It emphasizes the crucial role of integrating radiological, pathological, genomic, and clinical data in uncovering deeper biological insights. Furthermore, it outlines the typical workflow involved in developing and deploying deep learning applications for NSCLC and lists some currently used models, including convolutional neural networks for image analysis and complex architectures for multi-omics data integration. These models show considerable potential for improving diagnostic accuracy and optimizing therapeutic interventions. However, translating these computational tools into routine clinical practice faces several challenges. The review candidly addresses key issues, including the need for large-scale, high-quality, and standardized datasets; the "black box" nature of complex models, which requires improved interpretability to gain clinicians' trust and provide actionable insights; and profound ethical considerations regarding data privacy, algorithmic bias, and equitable access. Despite these obstacles, deep learning has emerged as a powerful instrument in the oncological arsenal, significantly enhancing the precision and efficiency of NSCLC care. Finally, the article offers a dialectical perspective on the future of deep learning in NSCLC, exploring emerging trends and providing recommendations to overcome current limitations, with the goal of maximizing its potential to improve patient survival and quality of life.

Indexed as

deep learningmultimodal data fusionmulti-omics dataNon-small cell lung cancer (NSCLC)precision care

Identifiers

PMID40948833
PMCPMC12432638

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.